Adagrasib provides antitumor activity against metastatic KRAS G12C-mutated colorectal cancer as monotherapy and in combination with cetuximab.
1. The overall tumor response to monotherapy with adagrasib was 23% and 46% in combination with cetuximab. 2. The median progression-free survival was 5.6 months on adagrasib monotherapy and 6.9 months on combination therapy with cetuximab. The level of classification of evidence: 2 (good) Study rundown: An oncogene homolog of the Kirsten rat sarcoma virus … Read more